Both the single-arm, open-label Phase II clinical study (KEYNOTE-158) in advanced patients with 11 solid tumors and the global, multicenter, Phase Ib clinical study (KEYNOTE-028) in patients with PD-L1-positive advanced solid tumors reported anti-tumor efficacy of pembrolizumab. The gene discussed is CD274; the disease is neoplasm.